Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. In a statistically ...
We’re seeing all sorts of new and exciting innovations in the world of electric bicycles, with developments in motor and drivetrain technology being key industry drivers. As it would turn out, ...
Intra-Cellular Therapies develops small-molecule drugs targeting the central nervous system for neuropsychiatric and neurological disorders. Caplyta is their lead drug, approved by the FDA for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results